What is AUPH's market cap?

$2.29B, based on the Nov 4 close of $17.11.

What is AUPH's P/E ratio?

7.3× trailing-twelve-month earnings of $314.27M.

Does Aurinia Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of AUPH is sold short?

7.8M shares, 7.3% of float, as of Oct 15, 2026.

What sector is AUPH in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · AUPHHealthcarePharmaceuticals

Aurinia Pharmaceuticals Inc (AUPH)

$17.11+3.32%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$16.56▲ 25.74% in range

Nov 3, 2025Low $13.17 · High $18.62Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Aurinia Pharmaceuticals closed at $17.11 on Nov 4, up 3.32%, 8.1% below its 52-week closing high. Volume of 1.5M shares was 1.75× its 20-day average (above normal).

Split-adjusted performance: +9.1% over one month, +5.3% over six months, +29.9% over one year.

In the quarter ended Sep 30, 2026, revenue was $83.70M, up 13.9% from a year earlier, with a net margin of 37.9%.

Short interest was 7.8M shares at the Oct 15 settlement, down 1.8% from the prior report (7.3% of float, 9.0 days to cover).

Market cap$2.29B134.0M shares

Revenue · quarter$83.7M+13.9% YoY

Diluted EPS$0.230.0% YoY

P/E · TTM7.3×P/S 7.1×

Net margin37.9%Gross 90.1%

Dividend yieldNone

52-week range13.17 – 18.62−8.1% from high

Volume1.5M1.75× 20-day avg

Volatility · 60d31.0%Annualised

Short % of float7.3%9.0 days to cover

Net cash$431.7MCash $486.9M

Next earnings—Not scheduled

Split-adjusted performance

1W −1.4%1M +9.1%3M +6.1%6M +5.3%YTD +7.3%1Y +29.9%3Y +132.8%5Y −42.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum75

Revenue growth60

Net margin91

Value (low P/E)79

Size83

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short7.8M−1.8% vs prior

Days to cover9.0Settled Oct 15

% of float7.3%

Short vol. 10d40.9%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
AUPHAurinia Pharmaceuticals	$17.11	+3.32%	+5.3%	+13.9%	37.9%	7.3	$2.29B
BHVNBiohaven	$15.24	−2.37%	+51.8%	—	—	—	$2.30B	Compare
IMNMImmunome	$19.52	−3.89%	−16.1%	−100.0%	—	—	$2.30B	Compare
VERAVera Therapeutics	$31.97	+4.10%	−12.6%	—	—	—	$2.30B	Compare
PVLAPalvella Therapeutics	$162.28	+6.11%	+24.7%	—	—	—	$2.34B	Compare
SEPNSepterna	$47.88	+9.57%	+93.8%	+22375.6%	−48.7%	—	$2.23B	Compare
TRLVTrulieve Cannabis	$11.60	+0.52%	—	—	−149.8%	—	$2.23B	Compare
ZYMEZymeworks	$30.94	+2.69%	+12.1%	−90.6%	−980.8%	—	$2.22B	Compare
PRGOPERRIGO	$15.83	+0.83%	+29.1%	−3.2%	7.3%	—	$2.20B	Compare

News about Aurinia Pharmaceuticals

All news →

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to DeclineZacks Investment Research · Oct 27, 2026Neutral Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-TermZacks Investment Research · Oct 23, 2026▲ Positive

Quick answers

What does Aurinia Pharmaceuticals do?: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis.
What is AUPH's market cap?: $2.29B, based on the Nov 4 close of $17.11.
What is AUPH's P/E ratio?: 7.3× trailing-twelve-month earnings of $314.27M.
Does Aurinia Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of AUPH is sold short?: 7.8M shares, 7.3% of float, as of Oct 15, 2026.
What sector is AUPH in?: Healthcare, in the Pharmaceuticals industry.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

HQ: Edmonton, A0128 employeesListed Oct 21, 2009auriniapharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology